This is a joint post with Rachel Silverman.
Through our Value for Money working group, we’ve spent much of the past year immersed in the world of global health funding agencies. With so many new agencies, particularly in the last quarter century (Figure 1), understanding the intricacies of the global health family can be daunting, even for the most devoted observers.
Officials from 50 of the world's poorest countries just announced the pre-launch of a new initiative to fight one of the greatest scourges in global health. The Global Partnership to Battle Donor Attention Deficit Disorder (to be known as GloPBADD) will develop preventive and therapeutic drugs and devices to increase the ability of those in the global health community to sustain their attention for up to two decades - the period over which the major returns to investments in health system capacity strengthening are likely to be observed.